Glaukos director granted options, corrects strike price

GLAUKOS Corp director Denice Torres reported a stock option grant and corrected prior disclosure details.

Rhea-AI Filing Summary

GLAUKOS Corp director Denice Torres reported a stock option grant and corrected prior disclosure details. She received options for 2,987 shares of common stock at an exercise price of $106.52 per share, granted under the issuer's Director Compensation Policy. The options vest in full on the one-year anniversary of the May 28, 2026 grant date and expire on May 28, 2036. This Form 4/A also amends a prior Form 4 that mistakenly reported the exercise price as $53.57, clarifying that the correct exercise price is $106.52.

Insider Trade Summary

Grant/Award: 2,987 shares

Grant/Award 1 txn

Insider Torres Denice

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	2,987	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 2,987 contracts (Direct)

Footnotes (2)

1. F1. This Form 4A amends a Form 4 filed June 1, 2026 that incorrectly reported the exercise price of options granted to the Reporting Person on May 28, 2026 as $53.57. The correct exercise price for the options granted is $106.52, as shown above.
2. F2. Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date.

Key Figures

Options granted: 2,987 options Exercise price (corrected): $106.52 per share Previously reported exercise price: $53.57 per share +2 more

5 metrics

Options granted 2,987 options Stock Option (Right to Buy) granted May 28, 2026

Exercise price (corrected) $106.52 per share Exercise price for options granted May 28, 2026

Previously reported exercise price $53.57 per share Incorrect price disclosed in Form 4 filed June 1, 2026

Total options after transaction 2,987 options Total derivative holdings following this grant

Option expiration date May 28, 2036 Expiration date of granted stock options

Key Terms

Stock Option (Right to Buy), exercise price, Director Compensation Policy, vests in full

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"incorrectly reported the exercise price of options granted"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Director Compensation Policy financial

"Granted pursuant to the Issuer's Director Compensation Policy."

vests in full financial

"Vests in full on the one-year anniversary of grant date."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GLAUKOS Corp (GKOS) report for Denice Torres?

GLAUKOS Corp reported that director Denice Torres received a grant of stock options for 2,987 shares of common stock. The options have an exercise price of $106.52 per share, were granted on May 28, 2026, and vest in full one year after the grant date.

Why did GLAUKOS Corp (GKOS) file an amended Form 4/A for Denice Torres?

The amended Form 4/A corrects an error in a previous Form 4 filed June 1, 2026. That earlier filing incorrectly reported the exercise price of options granted on May 28, 2026 as $53.57. The amendment clarifies the correct exercise price is $106.52 per share.

What are the key terms of Denice Torres’ stock option grant at GLAUKOS Corp (GKOS)?

Denice Torres received stock options to purchase 2,987 shares of GLAUKOS common stock at an exercise price of $106.52. The options were granted under the company’s Director Compensation Policy, vest in full on the one-year anniversary of the grant date, and expire on May 28, 2036.

How many shares can Denice Torres acquire from her new GLAUKOS Corp (GKOS) options?

The stock option grant allows Denice Torres to acquire 2,987 shares of GLAUKOS common stock if she exercises all the options. Her total derivative holdings reported following this transaction are 2,987 options, each representing the right to buy one share at $106.52.

When do Denice Torres’ GLAUKOS Corp (GKOS) stock options vest and expire?

The options granted to Denice Torres vest in full on the one-year anniversary of the May 28, 2026 grant date, aligning with the Director Compensation Policy. They have an expiration date of May 28, 2036, after which any unexercised options would no longer be exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 07:22 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Torres Denice

(Last) (First) (Middle)

C/O GLAUKOS CORPORATION

ONE GLAUKOS WAY

(Street)

ALISO VIEJO CALIFORNIA 92656

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GLAUKOS Corp [ GKOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
06/01/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$106.52(1)	05/28/2026		A		2,987		05/28/2027(2)	05/28/2036	Common Stock	2,987	$0	2,987	D

Explanation of Responses:

1. This Form 4A amends a Form 4 filed June 1, 2026 that incorrectly reported the exercise price of options granted to the Reporting Person on May 28, 2026 as $53.57. The correct exercise price for the options granted is $106.52, as shown above.

2. Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date.

	Diana Scherer, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)